Preimplantation genetic testing for sickle cell disease: a cost-effectiveness analysis
Preimplantation genetic testing for sickle cell disease: a cost-effectiveness analysis
Blog Article
Objective: To evaluate the cost-effectiveness of in vitro fertilization with preimplantation genetic testing for monogenic disease (IVF + PGT-M) in the conception of a nonsickle cell disease (non-SCD) individual compared with standard of care treatment for a naturally conceived, sickle cell disease (SCD)-affected individual.Design: A Markov simulation model was constructed to evaluate a one-time IVF + PGT-M treatment compared with the lifetime standard of care costs of treatment for Sokrates jako wychowawca. Sokratejskie rozmyślania Jana Patočki an individual potentially born with SCD.Using an annual discount rate of 3% for cost and outcome measures, quality-adjusted life years were constructed from utility weights and life expectancy values and then used as the effectiveness measurement.An incremental cost-effectiveness ratio was calculated for both treatment arms, and a willingness-to-pay threshold of $50,000 per quality-adjusted life year was assumed.Setting: Tertiary care or university medical center.
Patient(s): A hypothetical cohort of 10,000 patients was analzyed over a lifetime horizon using yearly cycles.Intervention(s): In vitro fertilization with preimplantation genetic testing for monogenic disease use in conception of a non-SCD individual.Main Outcome Measure(s): The primary outcomes of interest were the incremental Impacts of Future Grassland Changes on Surface Climate in Mongolia cost and effectiveness of an IVF+PGT-M conception compared with the SOC treatment of an SCD-affected individual.Result(s): In vitro fertilization with preimplantation genetic testing for monogenic disease was the optimal strategy in 93.17% of the iterations.
An incremental savings of $137,594 was demonstrated with a gain of 1.96 QALYs and 3.69 life years over a lifetime.Sensitivity analysis demonstrated that SOC treatment never met equivalent cost-effectiveness.Conclusion(s): Our model demonstrates that IVF + PGT-M for selection against SCD, compared with lifetime SOC treatment for those affected, is the most cost-effective strategy within the United States healthcare sector.